Fitusiran
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Transforming Hemophilia Treatment With Novel Rebalancing Agents: Clinical Studies and Practical Perspectives.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: September 03, 2026
Advances in treatments for hemophilia A/B with inhibitors: current treatment gaps and promising therapies.
Journal: Expert review of hematology
Published: July 08, 2026
RNA therapeutics and their delivery methods: a paradigm for haemophilia management.
Journal: Journal of drug targeting
Published: May 11, 2026
Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: April 28, 2026
Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: April 03, 2026
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Journal: The Cochrane database of systematic reviews
Published: March 24, 2026
Fitusiran treatment modulates the ratio between alpha- and beta-antithrombin isoforms.
Journal: HemaSphere
Published: March 04, 2026
Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: March 03, 2026
Toward a Platform PBPK Model to Characterize the Plasma and Tissue Disposition of Unconjugated Antisense Oligonucleotides and GalNAc-Conjugated Small Interfering RNAs in Preclinical Species and Human.
Journal: Clinical pharmacology and therapeutics
Published: February 24, 2026
Redefining hemophilia management: treatment goals, nonfactor replacement therapies, and the role of fitusiran.
Journal: The American journal of managed care
Published: January 21, 2026
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.
Journal: British journal of pharmacology
Published: January 16, 2026
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 12, 2026
Last Updated: 11/08/2026